Iovance Biotherapeutics Inc. Common Stock vs VanEck Rare Earth/Strategic Metals — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.75B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 3.5× VanEck Rare Earth/Strategic Metals's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| IOVA | REMX | |
|---|---|---|
Market Cap | $6.04B | $1.75B |
Volume | 14,805,993 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $14.82 | $109.53 |
52-Week Low | $1.81 | $60.58 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $5.97B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.97, down 1.47% with a bearish technical outlook. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 14 suggest potential oversold conditions. Recent news highlights strategic importance of rare earth metals amid U.S. efforts to reduce dependence on China, with Bank of America increasing its stake by 72.1% in the latest quarter.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China exposure. While geopolitical trends support long-term demand, current technical weakness and sector-specific risks warrant caution. The reshoring trade provides structural tailwinds, but investors should be prepared for elevated price swings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →